iwNHL 2018 Session VI

Novel Lymphoma Targets/Agents

In session VI of iwNHL 2018, John Kuruvilla, MD, FRCPC, Ryan Wilcox, MD, Francisco Hernandez Ilizaliturri, MD, Laurie Sehn, MD, and Kieron Dunleavy, MD, discussed a variety of novel therapy options.

Presentations
Selinexor: Best Partner To Combine with
John Kuruvilla
Princess Margaret Cancer Centre, Toronto, Canada
23 September, 2018

John Kuruvilla, MD, FRCPC from Princess Margaret Cancer Centre, Toronto, Canada, gives a talk on selinexor, an investigational anti-cancer agent targeting nuclear export.

SYK-JAK Inhibitor: Certulatinib Versus Other SYK Inhibitors
Ryan Wilcox
University of Michigan Rogel Cancer Center, Ann Arbor, MI
23 September, 2018

Ryan Wilcox, MD, from University of Michigan Rogel Cancer Center, Ann Arbor, MI, speaks on the clinical activity of cerdulatinib in non-Hodgkin lymphoma.

MCL-1 Inhibitors
Francisco Hernandez Ilizaliturri
Roswell Park Comprehensive Cancer Center, Buffalo, NY
23 September, 2018

Francisco Hernandez Ilizaliturri, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the role of MCL-1 in B-cell malignancies.

Polatuzumab - Including Combination Regimen in R/R NHL
Laurie Sehn
British Columbia Cancer Centre for Lymphoid Cancer, Canada
23 September, 2018

Laurie Sehn, MD, from British Columbia Cancer Centre for Lymphoid Cancer, Canada, talks about the potential use of polatuzumab vedotin in treating non-Hodgkin lymphoma,

Optimal Therapy for MYC-positive, Double-Hit & Triple-Hit DLBCL
Kieron Dunleavy
George Washington University, Washington, DC
23 September, 2018

Kieron Dunleavy, MD, from George Washington University, Washington, DC, speaks on the therapy options for MYC-positive, double-hit and triple-hit diffuse large B-cell lymphoma (DLBCL).